🍪 TalkPeptides uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
Forums›Public Square›Has anyone dealt with adolescent obesity: aap guidelines and glp-1 use in minors? › Page 2

Has anyone dealt with adolescent obesity: aap guidelines and glp-1 use in minors?

josh_phd_bmore Tue, Jan 9, 2024 at 10:52 AM 12 replies 2,199 viewsPage 2 of 3
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
Jan 9, 2024 at 4:50 PM#6
Dr.BariatricHTX said:
Read four things before the headline number.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

I would rather be corrected than agreed with, if it comes to it.

21 24rachel_ABQ, traveltech_sara, AttorneyGrant and 18 others
Reply Quote Save Share Report
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Jan 9, 2024 at 7:10 PM#7
I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same…
...regarding the trial evidence...

I think this is an underappreciated point. To expand on it with some data:

A recent meta-analysis of 12 RCTs (n=8,400) found that the trial evidence was associated with a significant effect size across diverse patient populations[1].

The NNT was 8, which is comparable to statins for secondary prevention. That's a strong clinical argument for this approach.

22 0Dr.PathRoch, mona_PHX, andrew_nyc and 19 others
Reply Quote Save Share Report
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Jan 9, 2024 at 9:30 PM#8
I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 18,000 GLP-1 users vs matched controls showed reduced MI incidence (HR 0.78) over 4 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
Last edited: Jan 10, 2024 at 2:30 AM
23 1jennifer_SEA, tyler_CSCS, VanRx_Mike and 20 others
Reply Quote Save Share Report

PeptideDetective — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Jan 9, 2024 at 11:50 PM#9

One thing that is still open after Dr.PulmRoch’s answer:

How long did you give it before you decided it was working?

24 2LarryQC_SD, wanda_boise, NurseAsh_DET and 21 others
Reply Quote Save Share Report
josh_phd_bmore
OPMember
389
1,678
Jul 2024
Baltimore, MD
Jan 10, 2024 at 11:01 AM#10

Reporting back.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

18 18tampaLisa73, KarenAZ_mom, zoe_NC and 15 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register
Threads · Members · Forums
semaglutidetirzepatideretatrutidecompoundingbloodworkside effects